Int'l Vaccine Institute to lead clinical trial in Nepal Sanofi and GSK received approval for their Phase 3 clinical study in Nepal to assess the safety, efficacy, and immunogenicity of their adjuvanted recombinant-protein COVID-19 vaccine candidate. Nepal 01 Oct, 2021
